BioClinica™, Inc. (NASDAQ: BIOC), a global provider of clinical trial management services, will attend and speak at several key industry conferences throughout the third and fourth quarters of 2010. Key BioClinica experts will provide insight into current industry news and trends, as well as the Company’s expanded suite of technology capabilities and offerings. The upcoming events include:
September 14-15, 2010
CBI’s 4th Annual Oncology Clinical Trials Summit
Jennifer Price, Director of Clinical Data Solutions at BioClinica, will present on September 15 at 1:40 p.m. on “Partnering Strategies for Successful Study Design and Data Collection in Oncology Trials.” During this presentation attendees will learn how to put together the clinical data collection strategy within the desired timelines. BioClinica will also showcase its Image Core Lab services and eClinical Solutions.
September 29-30, 2010
Outsourcing in Clinical Trials Northeast
Booth # 27
Outsourcing in Clinical Trials brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. This event will cover topics such as selecting a partner that will enable clinical trial managers to meet their goals on time and within budget. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.
October 11-13, 2010
DIA 4th Annual Clinical Forum
Lisboa Congress Centre
Jonathan Andrus, CCDM, Vice President, Data and Study Operations will present on October 11 from 9:00 a.m. - 12:30 p.m. on Electronic Data Capture (EDC) and Electronic Patient Reported Outcomes (ePRO), tools that are routinely used in hundreds of clinical trials each day. This interactive tutorial will look at the many aspects of EDC and ePRO that are particularly important from data management and clinical trial management viewpoints.
October 17-20, 2010
2010 Society for Clinical Data Management Annual Conference
Booth #s 306 and 308
Jonathan Andrus, CCDM, Vice President, Data and Study Operations will present on October 19 at 3:30 p.m. on Working Together for Quality Data. During this session he will discuss how to leverage skills and systems to achieve collaborative relationships and consistently deliver BioClinica’s excellent customer service and quality, timely and cost-effective clinical trial data from subject to database to clinical programming and reporting. BioClinica will also display it eClinical Services at booths 306 & 308.
October 20-21, 2010
8th Annual Clinical Trial Supply Conference East Coast 2010
Nick Lenares, Chief Product Architect, will present “Optimizing the Clinical Supply Chain with Simulation” on October 21 at 11:30 a.m. During this presentation he will discuss the current and future state of the industry and how toanalyze the clinical supply chain before and during the trial. BioClinica will also showcase its Optimizer clinical supply simulation solution.
November 17-18, 2010
9th Annual Partnerships in Clinical Trials Congress and Exhibition 2010
Booth # 419
The 9th Annual Partnerships in Clinical Trials is Europe's largest and most productive networking opportunity for clinical development outsourcing professionals. This conference brings together the most innovative thinkers in clinical development outsourcing from sponsors, CROs and other service providers.
November 23-26, 2010
International Union Against Cancer
Dedicated Training Course “Oncology Drug Development in Practice”
Amsterdam, The Netherlands
Dr. Klaus Noever, Vice President, Business Development and Clinical Affairs, Europe and Japan, will present on medical image management and tumor response evaluation on November 25 during an all-day session beginning at 9:00 a.m. This intensive training course is primarily designed to provide specific knowledge on the preclinical and clinical development of new agents intended for treatment of cancer, particularly in Europe. The course will also address strategic, regulatory and scientific issues in the development of such agents.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.